ACTRN12609000081213进行中（未招募）3 期
A 12 week prospective study of efficacy and acceptability of magnesium sulfate once weekly in adults as a management regime for constipation.
Colocap Pharmaceuticals Pty Ltd0 个研究点目标入组 100 人开始时间: 2009年2月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 79 Years（—）
- 性别
- All
入选标准
- •Diagnosis of constipation (defined as difficulty with rectal evacuation requiring oral or topical laxatives at least once weekly) for at least 6 months.
排除标准
- •Known adverse reaction to magnesium sulfate.
- •Known renal failure.
- •Pregnancy or breastfeeding.
研究者
相似试验
进行中（未招募）
不适用
A 12-week study to evaluate the effectiveness and safety of Fp Spiromax® using a range of doses, given twice daily compared with a non-active drug in Adolescent and Adult subjects with persistent Asthma uncontrolled on non-steroidal therapyEUCTR2010-023600-27-PLTeva Branded Pharmaceutical Products R&D, Inc.623
进行中（未招募）
不适用
A 12-Week Dose-ranging Study to Evaluate the Effectiveness and Safety of Fp Spiromax® given Orally Twice Daily compared with a non-active drug in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on High dose Inhaled Corticosteroid Therapy.AsthmaEUCTR2010-023601-35-BGTeva Branded Pharmaceutical Products R&D, Inc.600
进行中（未招募）
不适用
A 12-Week Dose-ranging Study to Evaluate the Effectiveness and Safety of Fp Spiromax® given Orally Twice Daily compared with a non-active drug in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on High dose Inhaled Corticosteroid Therapy.Severe Persistent AsthmaEUCTR2010-023601-35-PLTeva Branded Pharmaceutical Products R&D, Inc.600
进行中（未招募）
不适用
A 12-week study to evaluate the effectiveness and safety of Fp Spiromax® using a range of doses, given twice daily compared with a non-active drug in Adolescent and Adult subjects with persistent Asthma uncontrolled on non-steroidal therapyPersistent AsthmaEUCTR2010-023600-27-HUTeva Branded Pharmaceutical Products R&D, Inc.627
进行中（未招募）
1 期
A 12-Week Dose-ranging Study to Evaluate the Effectiveness and Safety of Fp Spiromax® given Orally Twice Daily compared with a non-active drug in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on High dose Inhaled Corticosteroid Therapy.EUCTR2010-023601-35-ESTeva Branded Pharmaceutical Products R&D, Inc.889